Rovalpituzumab tesirine
- Generic Name
- Rovalpituzumab tesirine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1613313-09-9
- Unique Ingredient Identifier
- P256HB60FF
- Background
Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Long-Term Study of Rovalpituzumab Tesirine
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT03543358
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 204818, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center /ID# 204885, Duarte, California, United States
🇺🇸Univ of Pittsburgh Med Ctr /ID# 204763, Pittsburgh, Pennsylvania, United States
Expanded Access to Rovalpituzumab Tesirine
- Conditions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03503890
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03334487
- Locations
- 🇺🇸
VA Central California Health C /ID# 170951, Fresno, California, United States
🇺🇸St. Luke's University Hospital /ID# 171374, Duluth, Minnesota, United States
🇧🇷Bahia Oncology Center - NOB /ID# 201272, Salvador, Bahia, Brazil
A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 29
- Registration Number
- NCT03086239
- Locations
- 🇯🇵
National Cancer Ctr Hosp East /ID# 161432, Kashiwa-shi, Chiba, Japan
🇯🇵Kyushu University Hospital /ID# 161430, Fukuoka-shi, Fukuoka, Japan
🇯🇵Kinki University -Osakasayama Campus /ID# 161431, Osakasayama-shi, Osaka, Japan
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 444
- Registration Number
- NCT03061812
- Locations
- 🇺🇸
Georgia Cancer Center /ID# 160206, Atlanta, Georgia, United States
🇺🇸Cedars-Sinai Medical Center /ID# 157102, Beverly Hills, California, United States
🇺🇸Mitchell Cancer Institute /ID# 158151, Mobile, Alabama, United States
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 748
- Registration Number
- NCT03033511
- Locations
- 🇺🇸
Parkland Health and Hosp Syste /ID# 170933, Dallas, Texas, United States
🇺🇸LA Hem-Oncology Med Group /ID# 156717, Los Angeles, California, United States
🇺🇸Thomas Jefferson University /ID# 156719, Philadelphia, Pennsylvania, United States
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 42
- Registration Number
- NCT03026166
- Locations
- 🇺🇸
University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States
🇺🇸University of Chicago /ID# 161006, Chicago, Illinois, United States
🇪🇸Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000257
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, United States
🇺🇸The University of Chicago Medical Center /ID# 157375, Chicago, Illinois, United States
🇺🇸Virginia Cancer Specialists - Fairfax /ID# 157377, Fairfax, Virginia, United States
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Stemcentrx
- Target Recruit Count
- 46
- Registration Number
- NCT02874664
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT02819999
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University Hospital of Cleveland, Cleveland, Ohio, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.